Sign in

    Anthony Occhiogrosso

    Research Analyst at Citigroup Inc.

    Anthony Occhiogrosso is an analyst at Citigroup Inc., focusing on comprehensive equity research and financial analysis within the banking and financial services sector. Leveraging advanced valuation techniques and industry insights, he covers major U.S. banks and financial institutions, delivering actionable investment recommendations and timely market analysis. Throughout his tenure at Citigroup, which began following prior experience in financial research roles at other leading firms, Occhiogrosso has established a strong reputation for accurate forecasting and robust investment performance. He holds FINRA securities licenses and is recognized for his expertise in fundamental analysis, industry regulation, and quantitative modeling.

    Anthony Occhiogrosso's questions to HAEMONETICS (HAE) leadership

    Anthony Occhiogrosso's questions to HAEMONETICS (HAE) leadership • Q1 2026

    Question

    Anthony Occhiogrosso, on for Joanne Wuensch, asked if the outlook for U.S. plasma collections had changed, noting a shift in language from 'modest rebound' to 'possibility of a recovery.' He also inquired about the longevity of the growth benefit from the new heparinized TEG cartridge and the progress of its rollout.

    Answer

    CEO Christopher Simon confirmed the intentional language shift on plasma collections, stating the company remains conservative and is not building a significant recovery into its plan, which is driven by controllable factors like price and share gains. For Hemostasis Management, Simon described the heparinized cartridge rollout as being in the 'early innings,' calling its introduction a 'watershed moment.' He noted they are in about half of the top U.S. accounts and have converted about half of the TEG 5000 base, indicating a sustained growth opportunity.

    Ask Fintool Equity Research AI

    Anthony Occhiogrosso's questions to iRhythm Technologies (IRTC) leadership

    Anthony Occhiogrosso's questions to iRhythm Technologies (IRTC) leadership • Q2 2025

    Question

    Anthony Occhiogrosso of Citigroup Inc. asked for specifics on the volume contribution from innovative channel partners in Q2 and requested a timeline for when the 40 accounts in active discussion might come online.

    Answer

    President and CEO Quentin Blackford declined to provide a specific volume breakout but confirmed that the contribution from innovative channels stepped up from the 3% of revenue reported in Q1. He did not give a specific timeline for the 40 active discussions, stating it would be a steady cadence. He highlighted the new Lusim Health AI partnership as a key enabler for identifying at-risk patients within these channels.

    Ask Fintool Equity Research AI